The Ion Torrent™ Oncomine™ Dx Target Test is the first targeted next-generation sequencing (NGS) *in vitro* diagnostic test for non–small cell lung cancer (NSCLC), simultaneously delivering multiple biomarker results for multiple targeted therapies from one sample within four days.

**Did you know?**
- Many NSCLC biopsy samples are so small that they cannot be analyzed by some NGS tests, especially panels containing hundreds of genes
- It can take two weeks to get results if you send the biomarker test out;* and the average life expectancy of a metastatic NSCLC patient is only about 16 weeks

**Choosing the right genomic profiling test can make a difference for your patient**
The Oncomine Dx Target Test is the only FDA-approved NSCLC NGS test that can:
- Successfully sequence even small samples, meaning more patients can potentially access targeted therapies
- Generate results in a laboratory within four days, enabling faster treatment decisions

Ask your pathologist for the Oncomine Dx Target Test, and make the right choice for your patient

---


---

This test is now reimbursed by Medicare and the top 20 commercial payers, covering over 180 million US lives.
Figure 2. There are several biomarkers associated with NSCLC. Currently, five are targeted based on treatment (on the left side). Additional biomarkers have been recommended by scientific guidelines for adding potential value in the patient stratification process. The Oncomine Dx Target Test is the only available diagnostic test delivering identification of multiple biomarkers at once (on the right side). The test includes three biomarkers validated for selection of relevant targeted therapies (EGFR or ROS1 or BRAF), and 20 additional genes relevant for NSCLC pathogenesis, analytically validated for variant detection from NSCLC tissue.

** The test reports fusion/translocation variants for ROS1 only. The test only reports ALK, MET, and RET mutations and does not report ALK, MET, and RET fusions.

Figure 3. The Oncomine Dx Target Test is able to analyze a majority of patient samples. Unlike other NSCLC companion diagnostic (CDx) tests, the Oncomine Dx Target Test only requires a small amount of DNA and RNA (i.e., tissue). This is important as a majority of NSCLC biopsy samples are very small. Based on data on size of NSCLC routine clinical samples received by one laboratory, Oncomine Dx Test could analyze many more patient samples than other NGS CDx.

* NGS to take top spot as cancer biomarker testing broadens. CAP TODAY, June 2018.

** NGS to take top spot as cancer biomarker testing broadens. CAP TODAY, June 2018

If your pathology laboratory does not perform the Oncomine Dx Target Test, you can send samples to one of these reference laboratories:

<table>
<thead>
<tr>
<th>Reference lab</th>
<th>Telephone number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Genetics, Inc.</td>
<td>888-700-7110</td>
<td>cancergenetics.com</td>
</tr>
<tr>
<td>Integrated Oncology (a division of LabCorp)</td>
<td>800-447-5816</td>
<td>integratedoncology.com</td>
</tr>
<tr>
<td>Quest Diagnostics, Inc.</td>
<td>866-697-8378</td>
<td>questdiagnostics.com</td>
</tr>
<tr>
<td>NeoGenomics Laboratories, Inc.</td>
<td>866-776-5907</td>
<td>neogenomics.com</td>
</tr>
<tr>
<td>Phenopath, a Quest Diagnostics Company</td>
<td>888-927-4366</td>
<td>phenopath.com</td>
</tr>
</tbody>
</table>

Find out more at oncomine.com